PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Addictive Behaviors Reports5 citationsOpen Access

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov

View Full Paper
SPShruti PatilThe University of Texas Southwestern Medical CenterNJNandini JhaThe University of Texas Southwestern Medical CenterMJManish K. JhaThe University of Texas Southwestern Medical Center

Key Points

  • GLP-1 receptor agonists may impact treatment outcomes for substance use disorders, enhancing recovery processes.
  • The analysis reveals significant data from clinical trials focusing on behavioral and pharmacological interventions.
  • Systematic review across multiple studies demonstrates the potential benefits of using GLP-1 receptor agonists.
  • Research highlights a growing interest in the application of GLP-1 receptor modulation in addiction treatment.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Patil et al. (2026) studied this question.

synapsesocial.com/papers/69a75f47c6e9836116a2a89dhttps://doi.org/10.1016/j.abrep.2026.100671
Ask AI
Helpful
Bookmark
Share
View Full Paper